Improving cancer immunotherapy by targeting exosomal PD-L1
Targeting exosomal PDL1 to improve immunotherapy
This study is looking at how tiny particles called exosomes in your blood can help doctors figure out if immunotherapy will work for you if you have skin cancer, especially metastatic melanoma, so they can choose the best treatment for you and avoid side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10913379 on NIH RePORTER |
What this research studies
This research investigates how exosomes, which are tiny vesicles released by cells, can influence the effectiveness of immunotherapy in treating skin cancer, particularly metastatic melanoma. The focus is on measuring levels of exosomal PD-L1 in patients' blood to identify who is likely to benefit from anti-PD-1 treatments. By developing new assays, the goal is to predict patient responses to therapy early on, allowing for better treatment decisions and minimizing unnecessary side effects. This approach aims to enhance the precision of cancer treatment by directing patients to the most effective therapies based on their individual responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who are considering or currently undergoing anti-PD-1 therapy.
Not a fit: Patients with non-melanoma skin cancers or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy treatments for melanoma patients, reducing toxicities and improving outcomes.
How similar studies have performed: Previous research has shown promise in using biomarkers like exosomal PD-L1 to predict responses to immunotherapy, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Guo, Wei — Wistar Institute
- Study coordinator: Guo, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.